Alpelisib, a PI3K inhibitor, has been recently approved by the FDA for advanced or metastatic HER2-negative, hormone receptor positive with PIK3CA-mutation, that exhibits progression to endocrine therapy in breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.